SEC Form 4 · accession 0001209191-19-005440
EAGLE PHARMACEUTICALS, INC. · EGRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sander A Flaum
Director
Period of report
Jan 23, 2019
Accepted (ET)
Jan 25, 2019 · 8:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827871
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $42.40 | Jan 23, 2019 | A | 10,000 | A | — | Jan 23, 2029 | Common Stock | 10,000 | 10,000 | D |
Explanation of responses
- F1The option fully vests on January 23, 2020, subject to the Reporting Person's continuous service with the Issuer as of the vesting date.